Renaissance Technologies LLC Lowers Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Renaissance Technologies LLC trimmed its position in AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) by 8.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 453,014 shares of the medical instruments supplier’s stock after selling 43,100 shares during the period. Renaissance Technologies LLC owned 1.16% of AngioDynamics worth $9,269,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in AngioDynamics by 35.9% during the first quarter. JPMorgan Chase & Co. now owns 369,315 shares of the medical instruments supplier’s stock valued at $7,955,000 after buying an additional 97,632 shares during the period. Raymond James Financial Services Advisors Inc. increased its position in shares of AngioDynamics by 40.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 42,139 shares of the medical instruments supplier’s stock worth $908,000 after purchasing an additional 12,231 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in AngioDynamics by 26.7% in the first quarter. PNC Financial Services Group Inc. now owns 14,718 shares of the medical instruments supplier’s stock valued at $317,000 after purchasing an additional 3,097 shares in the last quarter. MetLife Investment Management LLC lifted its position in AngioDynamics by 61.6% during the first quarter. MetLife Investment Management LLC now owns 19,651 shares of the medical instruments supplier’s stock valued at $423,000 after purchasing an additional 7,490 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in AngioDynamics by 14.3% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,378 shares of the medical instruments supplier’s stock worth $719,000 after buying an additional 4,166 shares in the last quarter. 94.94% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Raymond James dropped their price objective on shares of AngioDynamics from $25.00 to $22.00 and set a “strong-buy” rating for the company in a report on Friday, January 6th.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Dave Helsel sold 4,633 shares of AngioDynamics stock in a transaction that occurred on Tuesday, January 31st. The stock was sold at an average price of $12.95, for a total value of $59,997.35. Following the transaction, the senior vice president now directly owns 19,189 shares of the company’s stock, valued at approximately $248,497.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.90% of the stock is currently owned by company insiders.

AngioDynamics Stock Down 7.2 %

Shares of ANGO opened at $11.61 on Tuesday. The firm has a market cap of $454.35 million, a P/E ratio of -13.99 and a beta of 0.62. AngioDynamics, Inc. has a 1 year low of $11.45 and a 1 year high of $24.87. The stock has a 50 day simple moving average of $13.26 and a two-hundred day simple moving average of $15.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.16 and a quick ratio of 1.30.

AngioDynamics (NASDAQ:ANGO – Get Rating) last released its earnings results on Thursday, January 5th. The medical instruments supplier reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. The company had revenue of $85.43 million for the quarter, compared to analyst estimates of $84.05 million. AngioDynamics had a negative net margin of 9.98% and a negative return on equity of 0.14%. On average, analysts forecast that AngioDynamics, Inc. will post 0.01 earnings per share for the current fiscal year.

About AngioDynamics

(Get Rating)

AngioDynamics, Inc is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products.